A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait

The aim of this study is to assess demographics, clinical features, treatment patterns, and the comorbidity burden and its impact on CML patients in the real-world clinical setting in Kuwait. Adult patients with Philadelphia positive-chromosome (Ph+ve) CML who have received at least one line of tyrosine kinase inhibitor (TKI) treatment, such as but not limited to imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib will be included. The study will use data from the hospital records of CML patients between January 2014 and January 2024.

NCT Number	NCT07454850
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Leukemia, Myeloid, Chronic-Phase
Enrollment	400 participants
Start Date	2026-08-30
Primary Completion	2026-10-16 (estimated)
Study Completion	2026-10-16 (estimated)
Updated on ClinicalTrials.gov	2026-07-22